|
US5019368A
(en)
|
1989-02-23 |
1991-05-28 |
Cancer Biologics, Inc. |
Detection of necrotic malignant tissue and associated therapy
|
|
US5283173A
(en)
|
1990-01-24 |
1994-02-01 |
The Research Foundation Of State University Of New York |
System to detect protein-protein interactions
|
|
NZ243082A
(en)
|
1991-06-28 |
1995-02-24 |
Ici Plc |
4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
|
|
AU661533B2
(en)
|
1992-01-20 |
1995-07-27 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
TW225528B
(https=)
|
1992-04-03 |
1994-06-21 |
Ciba Geigy Ag |
|
|
US5641875A
(en)
|
1993-09-30 |
1997-06-24 |
University Of Pennsylvania |
DNA encoding chimeric IgG Fc receptor
|
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
|
US5747498A
(en)
|
1996-05-28 |
1998-05-05 |
Pfizer Inc. |
Alkynyl and azido-substituted 4-anilinoquinazolines
|
|
MX9800215A
(es)
|
1995-07-06 |
1998-03-31 |
Novartis Ag |
Pirrolopirimidas y procesos para su preparacion.
|
|
GB9518220D0
(en)
|
1995-09-06 |
1995-11-08 |
Medical Res Council |
Checkpoint gene
|
|
US5760041A
(en)
|
1996-02-05 |
1998-06-02 |
American Cyanamid Company |
4-aminoquinazoline EGFR Inhibitors
|
|
GB9603095D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline derivatives
|
|
HU228446B1
(en)
|
1996-04-12 |
2013-03-28 |
Warner Lambert Co |
Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof
|
|
EP0907642B1
(en)
|
1996-06-24 |
2005-11-02 |
Pfizer Inc. |
Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
|
|
CA2265630A1
(en)
|
1996-09-13 |
1998-03-19 |
Gerald Mcmahon |
Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
|
|
EP0837063A1
(en)
|
1996-10-17 |
1998-04-22 |
Pfizer Inc. |
4-Aminoquinazoline derivatives
|
|
JPH10234372A
(ja)
|
1997-02-27 |
1998-09-08 |
Boehringer Mannheim Corp |
キメラ受容体を有する細胞とその作成方法、並びに その利用
|
|
CO4940418A1
(es)
|
1997-07-18 |
2000-07-24 |
Novartis Ag |
Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
|
|
US20020004041A1
(en)
|
1999-02-19 |
2002-01-10 |
Albert Matthew L. |
Methods for abrogating a cellular immune response
|
|
BRPI0108676B8
(pt)
|
2000-02-24 |
2021-05-25 |
Lilly Co Eli |
anticorpos humanizados que sequestram peptídeo amilóide beta e seus usos no tratamento de condições caracterizadas por formação de placas amiloides, bem como composição farmacêutica que compreende os referidos anticorpos
|
|
CA2402211A1
(en)
|
2000-03-08 |
2001-09-13 |
National Jewish Medical And Research Center |
Phosphatidyl serine receptors and uses thereof
|
|
AU2001245647A1
(en)
|
2000-03-14 |
2001-09-24 |
Idec Pharmaceuticals Corporation |
Antibodies that bind phosphatidyl serine and a method of their use
|
|
US20030072743A1
(en)
|
2000-05-05 |
2003-04-17 |
Matthew Albert |
Genetic manipulation of phagocytes for modulation of antigen processing and the immune response therefrom
|
|
US6995162B2
(en)
|
2001-01-12 |
2006-02-07 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
|
EP1406653A4
(en)
|
2001-06-29 |
2005-05-04 |
Univ Leland Stanford Junior |
T CELL REGULATION GENES AND METHOD OF USE THEREOF
|
|
US8709412B2
(en)
*
|
2001-06-29 |
2014-04-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Modulation of TIM receptor activity in combination with cytoreductive therapy
|
|
JP4547911B2
(ja)
|
2002-02-01 |
2010-09-22 |
アリアド・ファーマシューティカルズ・インコーポレイテッド |
リン含有化合物およびその用途
|
|
US20060002940A1
(en)
|
2002-03-15 |
2006-01-05 |
Jennifer Stevenson |
Method of immunotherapy
|
|
US7247303B2
(en)
|
2002-07-15 |
2007-07-24 |
Board Of Regents, The University Of Texas System |
Selected antibody CDRs for binding to aminophospholipids
|
|
WO2004067569A1
(en)
|
2003-01-27 |
2004-08-12 |
Crucell Holland B.V. |
Internalising human binding molecules against cd72
|
|
US8198020B2
(en)
|
2003-08-22 |
2012-06-12 |
Potentia Pharmaceuticals, Inc. |
Compositions and methods for enhancing phagocytosis or phagocyte activity
|
|
WO2005047860A2
(en)
|
2003-11-08 |
2005-05-26 |
Elan Pharmaceuticals, Inc. |
Antibodies to alpha-synuclein
|
|
TW200539890A
(en)
|
2004-03-12 |
2005-12-16 |
Brigham & Womens Hospital |
Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function
|
|
AU2005231685A1
(en)
|
2004-03-24 |
2005-10-20 |
Telos Pharmaceuticals Llc |
Compositions as adjuvants to improve immune responses to vaccines and methods of use
|
|
GB0414055D0
(en)
|
2004-06-23 |
2004-07-28 |
Univ Edinburgh |
Specific binding members and uses thereof
|
|
DK1853631T3
(en)
|
2005-01-24 |
2016-03-29 |
Univ Texas |
Fc-FUSION CONSTRUCTIONS BINDING TO PHOSPHATIDYLSERINE AND THERAPEUTIC APPLICATION THEREOF
|
|
US20060257359A1
(en)
|
2005-02-28 |
2006-11-16 |
Cedric Francois |
Modifying macrophage phenotype for treatment of disease
|
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
|
RU2429244C2
(ru)
|
2006-03-23 |
2011-09-20 |
Байоарктик Ньюросайенс Аб |
Улучшенные селективные в отношении протофибрилл антитела и их применение
|
|
NZ574188A
(en)
|
2006-07-14 |
2012-05-25 |
Ac Immune Sa |
Humanized antibody against amyloid beta
|
|
WO2008042814A2
(en)
|
2006-09-29 |
2008-04-10 |
California Institute Of Technology |
Mart-1 t cell receptors
|
|
AU2008298948B2
(en)
|
2007-09-12 |
2014-09-04 |
F. Hoffmann-La Roche Ag |
Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
|
|
US8354528B2
(en)
|
2007-10-25 |
2013-01-15 |
Genentech, Inc. |
Process for making thienopyrimidine compounds
|
|
AU2009328505B2
(en)
|
2008-12-19 |
2014-11-27 |
Panima Pharmaceuticals Ag |
Human anti-alpha-synuclein autoantibodies
|
|
ES2647823T3
(es)
|
2009-05-08 |
2017-12-26 |
Vaccinex, Inc. |
Anticuerpos anti-CD100 y métodos de uso de los mismos
|
|
US20110165649A1
(en)
|
2010-01-06 |
2011-07-07 |
Brett Tyler |
Methods and compositions to improve the health of plants, animals and microbes by manipulating protein entry into symbionts and their hosts
|
|
US20130071414A1
(en)
|
2011-04-27 |
2013-03-21 |
Gianpietro Dotti |
Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
|
|
WO2013074916A1
(en)
|
2011-11-18 |
2013-05-23 |
Board Of Regents, The University Of Texas System |
Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
|
|
WO2013192294A1
(en)
|
2012-06-20 |
2013-12-27 |
Boston 3T Biotechnologies, Inc. |
Cellular therapies for treating and preventing cancers and other immune system disorders
|
|
CA2881981A1
(en)
|
2012-08-20 |
2014-02-27 |
Fred Hutchinson Cancer Research Center |
Method and compositions for cellular immunotherapy
|
|
EP2906684B8
(en)
|
2012-10-10 |
2020-09-02 |
Sangamo Therapeutics, Inc. |
T cell modifying compounds and uses thereof
|
|
US20140162290A1
(en)
|
2012-11-22 |
2014-06-12 |
Riken |
Probe for detecting dead cell
|
|
WO2014153114A1
(en)
|
2013-03-14 |
2014-09-25 |
Fred Hutchinson Cancer Research Center |
Compositions and methods to modify cells for therapeutic objectives
|
|
WO2015066262A1
(en)
|
2013-11-04 |
2015-05-07 |
Trustees Of Dartmouth College |
Methods for preventing toxicity of adoptive cell therapy
|
|
EP3656864A1
(en)
|
2014-02-14 |
2020-05-27 |
Board of Regents, The University of Texas System |
Chimeric antigen receptors and methods of making
|
|
IL290655B2
(en)
|
2014-05-29 |
2024-05-01 |
Us Health |
Anti-human papillomavirus 16 E7 T-cell chelates
|
|
TWI664190B
(zh)
|
2014-06-27 |
2019-07-01 |
美商Ｃ２Ｎ醫療診斷有限責任公司 |
人類化抗－ｔａｕ抗體
|
|
ES2781175T3
(es)
*
|
2014-07-31 |
2020-08-31 |
Novartis Ag |
Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico
|
|
KR20250067191A
(ko)
|
2014-09-17 |
2025-05-14 |
노파르티스 아게 |
입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
|
|
US11161907B2
(en)
|
2015-02-02 |
2021-11-02 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
US20170151281A1
(en)
|
2015-02-19 |
2017-06-01 |
Batu Biologics, Inc. |
Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
|
|
WO2016176639A1
(en)
|
2015-04-30 |
2016-11-03 |
University Of Southern California |
Secretory tnt car cell immunotherapy
|
|
CN107995913B
(zh)
|
2015-05-18 |
2022-02-11 |
T细胞受体治疗公司 |
使用融合蛋白对tcr重编程的组合物和方法
|
|
US11116795B2
(en)
|
2015-07-10 |
2021-09-14 |
The Trustees Of The University Of Pennsylvania |
Treatment of a canine CD20 positive disease or condition using a canine CD20-specific chimeric antigen receptor
|
|
RU2766690C2
(ru)
|
2015-07-28 |
2022-03-15 |
Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания |
Модифицированные моноциты/макрофаги, экспрессирующие химерные антигенные рецепторы, и их применения
|
|
EP3202792B1
(en)
|
2015-08-07 |
2024-08-14 |
Shenzhen In Vivo Biomedicine Technology Limited Company |
Chimeric antigen receptor containing intracellular domain of toll-like receptor
|
|
US11352439B2
(en)
|
2015-08-13 |
2022-06-07 |
Kim Leslie O'Neill |
Macrophage CAR (MOTO-CAR) in immunotherapy
|
|
CN106467573B
(zh)
|
2015-08-21 |
2021-05-25 |
佧珐药业有限公司 |
抗间皮素全人抗体以及靶向间皮素的免疫效应细胞
|
|
KR20180054600A
(ko)
|
2015-10-13 |
2018-05-24 |
브라이엄 영 유니버시티 |
면역치료에서의 대식세포 키메라 항원 수용체(moto-car)
|
|
MX2018005618A
(es)
|
2015-11-05 |
2018-08-01 |
Juno Therapeutics Inc |
Receptores quimericos que contienen dominios inductores de traf y composiciones y metodos relacionados.
|
|
WO2017083700A1
(en)
|
2015-11-13 |
2017-05-18 |
The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas |
Ligand-guided phagocytosis based therapy for treatment of alzheimer's disease and other neurodegenerative diseases
|
|
US20180186855A1
(en)
|
2016-03-23 |
2018-07-05 |
Alector Llc |
Chimeric receptors and methods of use thereof
|
|
US10875919B2
(en)
|
2016-04-26 |
2020-12-29 |
Alector Llc |
Chimeric receptors and methods of use thereof
|
|
AU2017271606B2
(en)
|
2016-05-27 |
2024-08-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
FLT3-specific chimeric antigen receptors and methods using same
|
|
CN107522786A
(zh)
|
2016-06-20 |
2017-12-29 |
深圳市体内生物医药科技有限公司 |
一种分子、表达其的细胞及其制备方法和用途
|
|
WO2018031419A1
(en)
|
2016-08-12 |
2018-02-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods for enhancing immunogenic cross-presentation of tumor antigens
|
|
EP4089116A1
(en)
|
2016-09-27 |
2022-11-16 |
Cero Therapeutics, Inc. |
Chimeric engulfment receptor molecules
|
|
WO2018132695A1
(en)
|
2017-01-13 |
2018-07-19 |
Celdara Medical, Llc |
Chimeric antigen receptors targeting tim-1
|
|
JP7164598B2
(ja)
|
2017-05-17 |
2022-11-01 |
サンダー・バイオテック・インコーポレイテッド |
トランスジェニックマクロファージ、キメラ抗原受容体、及び関連する方法
|
|
US10415017B2
(en)
|
2017-05-17 |
2019-09-17 |
Thunder Biotech, Inc. |
Transgenic macrophages, chimeric antigen receptors, and associated methods
|
|
WO2018220224A1
(en)
|
2017-06-02 |
2018-12-06 |
Medirista Biotechnologies Ab |
Lipid-related antigens and antibodies directed against them
|
|
EP3688032B1
(en)
|
2017-09-26 |
2025-11-05 |
Cero Therapeutics Holdings, Inc. |
Chimeric engulfment receptor molecules and methods of use
|
|
WO2019079529A1
(en)
|
2017-10-17 |
2019-04-25 |
The Translational Genomics Research Institute |
TREM2 AGONISTS FOR STIMULATING MICROGLIA AND IDENTIFICATION METHODS
|
|
GB201717974D0
(en)
|
2017-10-31 |
2017-12-13 |
Univ Court Of The Univ Of Aberdeen |
Modified receptors
|
|
US11866731B2
(en)
|
2017-11-10 |
2024-01-09 |
Chineo Medical Technology Co., Ltd |
Modified immune cells and uses thereof
|
|
CN111886028A
(zh)
|
2018-02-09 |
2020-11-03 |
达特茅斯大学理事会 |
用于治疗神经退行性疾病和障碍的嵌合抗原受体
|
|
RU2020135106A
(ru)
|
2018-03-28 |
2022-04-29 |
Серо Терапьютикс, Инк. |
Векторы экспрессии для химерных рецепторов поглощения, генетически модифицированные клетки-хозяева и их применения
|
|
US20210015865A1
(en)
|
2018-03-28 |
2021-01-21 |
Cero Therapeutics, Inc. |
Chimeric engulfment receptors and uses thereof for neurodegenerative diseases
|
|
WO2019191334A1
(en)
|
2018-03-28 |
2019-10-03 |
Cero Therapeutics, Inc. |
Chimeric tim4 receptors and uses thereof
|
|
JP7444781B2
(ja)
|
2018-03-28 |
2024-03-06 |
セロ・セラピューティクス・インコーポレイテッド |
細胞免疫療法組成物およびその使用
|
|
TWI809130B
(zh)
|
2018-06-22 |
2023-07-21 |
美商凱特製藥公司 |
嵌合跨膜蛋白及其用途
|
|
EP3876977A1
(en)
|
2018-11-06 |
2021-09-15 |
The Regents Of The University Of California |
Chimeric antigen receptors for phagocytosis
|
|
US20230158071A1
(en)
|
2018-12-07 |
2023-05-25 |
Crage Medical Co., Limited |
Tumor combined immunotherapy
|
|
CA3135531A1
(en)
|
2019-04-30 |
2020-11-05 |
Daniel Getts |
Engineered chimeric fusion protein compositions and methods of use thereof
|
|
US20220251217A1
(en)
|
2019-07-03 |
2022-08-11 |
The Regents Of The University Of California |
Immunotherapy targeting cell surface marker cd72 for the treatment of b-cell malignancies
|
|
WO2021067875A1
(en)
|
2019-10-03 |
2021-04-08 |
Cero Therapeutics, Inc. |
Chimeric tim4 receptors and uses thereof
|
|
US10980836B1
(en)
|
2019-12-11 |
2021-04-20 |
Myeloid Therapeutics, Inc. |
Therapeutic cell compositions and methods of manufacturing and use thereof
|
|
US20210253696A1
(en)
|
2020-01-21 |
2021-08-19 |
Cero Therapeutics, Inc. |
Bivalent chimeric engulfment receptors and uses thereof
|
|
WO2022036265A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Chimeric tim receptors and uses thereof
|
|
WO2022036287A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Anti-cd72 chimeric receptors and uses thereof
|
|
WO2022036285A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase
|
|
JP2024529474A
(ja)
|
2021-07-28 |
2024-08-06 |
セロ・セラピューティクス・インコーポレイテッド |
キメラＴｉｍ４受容体およびその使用
|